112 related articles for article (PubMed ID: 37602454)
1. Identification of a Diagnosis and Therapeutic Inflammatory Response-Related Gene Signature Associated with Esophageal Adenocarcinoma.
Xie Y; Li J; Tao Q; Zeng C; Chen Y
Crit Rev Eukaryot Gene Expr; 2023; 33(7):65-80. PubMed ID: 37602454
[TBL] [Abstract][Full Text] [Related]
2. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.
Lv J; Guo L; Wang JH; Yan YZ; Zhang J; Wang YY; Yu Y; Huang YF; Zhao HP
World J Gastroenterol; 2019 Jan; 25(2):233-244. PubMed ID: 30670912
[TBL] [Abstract][Full Text] [Related]
3. Identification of potential biomarkers in Barrett's esophagus derived esophageal adenocarcinoma.
Yi N; Zhao H; He J; Xie X; Liang L; Zuo G; Xiong M; Liang Y; Yi T
Sci Rep; 2023 Feb; 13(1):2345. PubMed ID: 36759514
[TBL] [Abstract][Full Text] [Related]
4. Novel Aberrations Uncovered in Barrett's Esophagus and Esophageal Adenocarcinoma Using Whole Transcriptome Sequencing.
Maag JLV; Fisher OM; Levert-Mignon A; Kaczorowski DC; Thomas ML; Hussey DJ; Watson DI; Wettstein A; Bobryshev YV; Edwards M; Dinger ME; Lord RV
Mol Cancer Res; 2017 Nov; 15(11):1558-1569. PubMed ID: 28751461
[TBL] [Abstract][Full Text] [Related]
5. Identification of miRNAs and genes for predicting Barrett's esophagus progressing to esophageal adenocarcinoma using miRNA-mRNA integrated analysis.
Yao C; Li Y; Luo L; Xiong Q; Zhong X; Xie F; Feng P
PLoS One; 2021; 16(11):e0260353. PubMed ID: 34818353
[TBL] [Abstract][Full Text] [Related]
6. MXD1 is a Potential Prognostic Biomarker and Correlated With Specific Molecular Change and Tumor Microenvironment Feature in Esophageal Squamous Cell Carcinoma.
Du F; Dong D; Zhang X; Jia J
Technol Cancer Res Treat; 2021; 20():15330338211052142. PubMed ID: 34761715
[No Abstract] [Full Text] [Related]
7. Epigenetic biomarkers in esophageal cancer.
Kaz AM; Grady WM
Cancer Lett; 2014 Jan; 342(2):193-9. PubMed ID: 22406828
[TBL] [Abstract][Full Text] [Related]
8. Decoding common genetic alterations between Barrett's esophagus and esophageal adenocarcinoma: A bioinformatics analysis.
Jalali P; Yaghoobi A; Rezaee M; Zabihi MR; Piroozkhah M; Aliyari S; Salehi Z
Heliyon; 2024 May; 10(10):e31194. PubMed ID: 38803922
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
10. Immune determinants of Barrett's progression to esophageal adenocarcinoma.
Lagisetty KH; McEwen DP; Nancarrow DJ; Schiebel JG; Ferrer-Torres D; Ray D; Frankel TL; Lin J; Chang AC; Kresty LA; Beer DG
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33290281
[TBL] [Abstract][Full Text] [Related]
11. Deciphering the unique microRNA signature in human esophageal adenocarcinoma.
Saad R; Chen Z; Zhu S; Jia P; Zhao Z; Washington MK; Belkhiri A; El-Rifai W
PLoS One; 2013; 8(5):e64463. PubMed ID: 23724052
[TBL] [Abstract][Full Text] [Related]
12. Differentially Infiltrated Identification of Novel Diagnostic Biomarkers Associated with Immune Infiltration in Nasopharyngeal Carcinoma.
Gao P; Lu W; Hu S; Zhao K
Dis Markers; 2022; 2022():3934704. PubMed ID: 36438903
[TBL] [Abstract][Full Text] [Related]
13. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
[TBL] [Abstract][Full Text] [Related]
14. Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.
Ray D; Ray P; Ferrer-Torres D; Wang Z; Nancarrow D; Yoon HW; San Martinho M; Hinton T; Owens S; Thomas D; Jiang H; Lawrence TS; Lin J; Lagisetty K; Chang AC; Beer DG
Gastroenterology; 2020 Feb; 158(3):583-597.e1. PubMed ID: 31715145
[TBL] [Abstract][Full Text] [Related]
15. Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.
Varghese S; Newton R; Ross-Innes CS; Lao-Sirieix P; Krishnadath KK; O'Donovan M; Novelli M; Wernisch L; Bergman J; Fitzgerald RC
Gastroenterology; 2015 Nov; 149(6):1511-1518.e5. PubMed ID: 26248086
[TBL] [Abstract][Full Text] [Related]
16. Distinct esophageal adenocarcinoma molecular subtype has subtype-specific gene expression and mutation patterns.
Guo X; Tang Y; Zhu W
BMC Genomics; 2018 Oct; 19(1):769. PubMed ID: 30355311
[TBL] [Abstract][Full Text] [Related]
17. Integrated PPI- and WGCNA-Retrieval of Hub Gene Signatures Shared Between Barrett's Esophagus and Esophageal Adenocarcinoma.
Nangraj AS; Selvaraj G; Kaliamurthi S; Kaushik AC; Cho WC; Wei DQ
Front Pharmacol; 2020; 11():881. PubMed ID: 32903837
[TBL] [Abstract][Full Text] [Related]
18. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer.
Jin Z; Olaru A; Yang J; Sato F; Cheng Y; Kan T; Mori Y; Mantzur C; Paun B; Hamilton JP; Ito T; Wang S; David S; Agarwal R; Beer DG; Abraham JM; Meltzer SJ
Clin Cancer Res; 2007 Nov; 13(21):6293-300. PubMed ID: 17975140
[TBL] [Abstract][Full Text] [Related]
20. Construction of the Interaction Network of Hub Genes in the Progression of Barrett's Esophagus to Esophageal Adenocarcinoma.
Li K; Duan P; He H; Du R; Wang Q; Gong P; Bian H
J Inflamm Res; 2023; 16():1533-1551. PubMed ID: 37077220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]